Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas

Detalhes bibliográficos
Ano de defesa: 2019
Autor(a) principal: Mendes, Edin?a Pastro lattes
Orientador(a): Echevarria, Aurea
Banca de defesa: Echevarria, Aurea, Santos, Eduardo Caio Torres dos, Santos, Fernanda Nunes, Silva, Lucia Helena Pinto da, Coelho, Irene da Silva
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal Rural do Rio de Janeiro
Programa de Pós-Graduação: Programa de P?s-Gradua??o em Ci?ncia, Tecnologia e Inova??o em Agropecu?ria
Departamento: Pr?-Reitoria de Pesquisa e P?s-Gradua??o
País: Brasil
Palavras-chave em Português:
Palavras-chave em Inglês:
Área do conhecimento CNPq:
Link de acesso: https://tede.ufrrj.br/jspui/handle/jspui/5651
Resumo: The leishmaniosis are a serious global public health problem, affecting patients with pronounced deformity, morbidity and mortality, as well as difficulty of access and adherence to treatment, lack of investment in the development of new drugs by pharmaceutical industry and inefficient social policies. The treatment used is not adequate due to drug effectiveness and toxicity. Additionally, resistance to available drugs has been shown by the sensitivity of several strains to these substances and treatment can be long and require hospitalization. In an attempt to find new anti-parasitic agents that can help with Leishmaniosis treatment, a series of seven chalcones-thiosemicarbazones with different substituents (CT-H, CT-Me, CT-CN, CT-F, CT-Br, CT-Cl and CT-NO2) against the promastigote forms of parasites of Leishmania spp was assessed. Evaluation started through the screening of different substances at 50?M concentration with promastigote forms of L. amazonensis, and when leishmanicidal activity was observed, a further evaluation with L. amazonensis, L. infantum and L. braziliensis was performed in the form of promastigotes at concentration range of 50 to 1.56 ?M dissolved in DMSO. Parasite cultures were prepared with Schneider?s medium supplemented with 10% or 20% of bovine fetal serum, arranged in 96 wells microplates and incubated at 26? C for 12 h. All trials were conducted in triplicate in three independent assays and pentamidine was used as positive control. The cytotoxicity of these compounds was assessed in uninfected cells with murine peritoneal macrophages in 24 h presenting LD50 values (?M) for CT-Br and CT-Cl 44.24 and 32.75 ?M respectively, demonstrating that those compounds are less cytotoxic than pentamidine whose value was = 8.5 . The promastigate forms were cultivated with and without these substances in Schneider?s culture medium and incubated at the 26? C for 12 hours using pentamidine isethionate as a reference drug. After incubation, the viability of the parasites was determined by using the MTT assay. The results showed that the CT-Cl was the most active compound for the three species tested, presenting IC50 = 5.22 ?M to L. amazonensis, 3.97 ?M to L. infantum and 3.89 ?M to L. braziliensis, respectively. Pentamidine presented IC50 = 5.20 ?M. The other compounds also obtained good results with IC50 in the range of 4.34 to 14.80 ?M. In trials of CT with the L. amazonensis axenic amastigotes IC50 values were obtained in the range of 6.18 to 14.74 ?M, indicating very interesting activity. This study also investigated the mechanism of action of most active substances in trypanothione reductase enzyme and the NO synthase pathways by evaluating nitric oxide. However, positive results were not observed to support those pathways as significant to chalcones-thiosemicarbazones action. The results obtained by the evaluation of chalcones-thiosemicarbazones action on the three species indicate this class of substances as potential antileishmanial agents.
id UFRRJ-1_ef053699b6fc32c7c7734cf423499ad2
oai_identifier_str oai:localhost:jspui/5651
network_acronym_str UFRRJ-1
network_name_str Biblioteca Digital de Teses e Dissertações da UFRRJ
repository_id_str
spelling Echevarria, AureaCPF: 668.742.388-68Cavalheiro, Marilene Marcuzzo do CantoCPF: 175.087.030-49Echevarria, AureaSantos, Eduardo Caio Torres dosSantos, Fernanda NunesSilva, Lucia Helena Pinto daCoelho, Irene da SilvaCPF: 706.903.407-53http://lattes.cnpq.br/6931787630199061Mendes, Edin?a Pastro2022-05-12T20:53:53Z2019-05-13MENDES, Edin?a Pastro. Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas. 2019. 73 f. Tese (Doutorado em Ci?ncia, Tecnologia e Inova??o Agropecu?ria) - Pr?-Reitoria de Pesquisa e P?s-Gradua??o, Universidade Federal Rural do Rio de Janeiro, Serop?dica, RJ, 2019.https://tede.ufrrj.br/jspui/handle/jspui/5651The leishmaniosis are a serious global public health problem, affecting patients with pronounced deformity, morbidity and mortality, as well as difficulty of access and adherence to treatment, lack of investment in the development of new drugs by pharmaceutical industry and inefficient social policies. The treatment used is not adequate due to drug effectiveness and toxicity. Additionally, resistance to available drugs has been shown by the sensitivity of several strains to these substances and treatment can be long and require hospitalization. In an attempt to find new anti-parasitic agents that can help with Leishmaniosis treatment, a series of seven chalcones-thiosemicarbazones with different substituents (CT-H, CT-Me, CT-CN, CT-F, CT-Br, CT-Cl and CT-NO2) against the promastigote forms of parasites of Leishmania spp was assessed. Evaluation started through the screening of different substances at 50?M concentration with promastigote forms of L. amazonensis, and when leishmanicidal activity was observed, a further evaluation with L. amazonensis, L. infantum and L. braziliensis was performed in the form of promastigotes at concentration range of 50 to 1.56 ?M dissolved in DMSO. Parasite cultures were prepared with Schneider?s medium supplemented with 10% or 20% of bovine fetal serum, arranged in 96 wells microplates and incubated at 26? C for 12 h. All trials were conducted in triplicate in three independent assays and pentamidine was used as positive control. The cytotoxicity of these compounds was assessed in uninfected cells with murine peritoneal macrophages in 24 h presenting LD50 values (?M) for CT-Br and CT-Cl 44.24 and 32.75 ?M respectively, demonstrating that those compounds are less cytotoxic than pentamidine whose value was = 8.5 . The promastigate forms were cultivated with and without these substances in Schneider?s culture medium and incubated at the 26? C for 12 hours using pentamidine isethionate as a reference drug. After incubation, the viability of the parasites was determined by using the MTT assay. The results showed that the CT-Cl was the most active compound for the three species tested, presenting IC50 = 5.22 ?M to L. amazonensis, 3.97 ?M to L. infantum and 3.89 ?M to L. braziliensis, respectively. Pentamidine presented IC50 = 5.20 ?M. The other compounds also obtained good results with IC50 in the range of 4.34 to 14.80 ?M. In trials of CT with the L. amazonensis axenic amastigotes IC50 values were obtained in the range of 6.18 to 14.74 ?M, indicating very interesting activity. This study also investigated the mechanism of action of most active substances in trypanothione reductase enzyme and the NO synthase pathways by evaluating nitric oxide. However, positive results were not observed to support those pathways as significant to chalcones-thiosemicarbazones action. The results obtained by the evaluation of chalcones-thiosemicarbazones action on the three species indicate this class of substances as potential antileishmanial agents.As leishmanioses s?o doen?as transmitidas por insetos vetores, flebotom?neos, infectados com parasitos do g?nero leishmania spp. e constituem um grave problema de sa?de p?blica mundial, al?m de estarem relacionadas entre as seis grandes endemias humanas. Essas doen?as apresentam uma ampla variedade de manifesta??es cl?nicas na sua forma cut?nea causando grande deformidade, e na forma visceral com elevado n?mero de morbidade e mortalidade se n?o for diagnosticada e tratatada. A caracter?stica limitante, pela dificuldade de acesso e ades?o ao tratamento, pela falta de investimentos na cria??o de novos f?rmacos pela ind?stria farmac?utica e pol?ticas sociais ineficientes. O tratamento utilizado n?o ? satisfat?rio em rela??o a efetividade e toxicidade, e h? resist?ncia aos f?rmacos dispon?veis, ocasionado pela sensibilidade de diversas cepas a estas subst?ncias, al?m de ser longo e requerer interna??o. Assim, objetivando encontrar novos agentes antiparasit?rios que possam auxiliar no tratamento das leishmanioses, foi avaliada uma s?rie de sete chalconas-tiossemicarbazonas, com diferentes grupos substituintes (CT-H, CT-Me, CT-CN, CT-F, CT-Br, CT-Cl e CT-NO2) frente ?s formas promastigotas de parasitos de Leishmania spp. As chalconas s?o produtos naturais amplamente distribu?dos nas plantas superiores que apresentam diversificada atividade biol?gica incluindo a antiparasit?ria. A utiliza??o das estruturas moleculares dessas subst?ncias como prot?tipos poder?o possibilitar a obten??o de novas subst?ncias com potencial atividade antiparasit?ria. A introdu??o de grupos moleculares da classe das tiossemicarbazonas, tamb?m com j? relatada atividade antiparasit?ria, poder? provocar a intera??o com enzimas dependentes de ferro presentes nos parasitos da fam?lia dos tripanossomat?deos favorecendo o efeito antiparasit?rio. Os primeiros resultados com as subst?ncias a 50 ?M testadas frente ?s formas promastigotas de L. amazonensis apresentaram uma boa atividade antileishmania. A avalia??o frente ?s L. amazonensis, L. infantum e L. braziliensis na forma de promastigotas em concentra??es na faixa de 1,56 a 50 ?M indicou efici?ncia dos prot?tipos, a pentamidina foi utilizada como controle positivo da rea??o. A citotoxicidade dos compostos, avaliada em c?lulas n?o infectadas de macr?fagos murinos em culturas de 72 h, apresentou valores de DL50 para CT-Br e CT-Cl 44,24 e 32,75 ?M, respectivamente, demonstrando serem menos citot?xicos do que a pentamidina. As formas amastigotas intracelulares foram avaliadas com e sem as subst?ncias em teste. A viabilidade dos parasitos foi determinada utilizando o ensaio de MTT. Os resultados mostraram que a CT-Cl foi o composto mais ativo para as tr?s esp?cies testadas. Apresentando IC50 na faixa de 5,22 ?M para L. amazonensis, 3,97 ?M para L. infantum e 3,89 ?M para L. braziliensis, respectivamente, e a pentamidina apresentou IC50 = 5,20 ?M. Os outros compostos tamb?m apresentaram bons resultados com IC50 na faixa de 4,34 a 14,80 ?M. Nos ensaios com amastigotas ax?nicas de L. amazonensis foram obtidos valores de IC50 na faixa de 6,18 a 14,74 ?M, indicando atividade promissora. Neste estudo, tamb?m foi investigado o mecanismo de a??o das subst?ncias mais ativas na via da enzima tripanotiona redutase e via NO sintase atrav?s da avalia??o de ?xido n?trico. No entanto, n?o foram observados resultados positivos que indicassem essas vias como significativas para a a??o das chalconas-tiossemicarbazonas. Os resultados obtidos frente as tr?s esp?cies avaliadas quanto a a??o de chalconas-tiossemicarbazonas, in?ditas, pela primeira vez relatadas nesse trabalho de tese, indicaram essa classe de subst?ncias como potenciais agentes antileishmania.Submitted by Jorge Silva (jorgelmsilva@ufrrj.br) on 2022-05-12T20:53:53Z No. of bitstreams: 1 2019 - Edin?a Pastro Mendes.pdf: 2588054 bytes, checksum: 87d33da433ee3426cb9cb1ee14afab29 (MD5)Made available in DSpace on 2022-05-12T20:53:53Z (GMT). No. of bitstreams: 1 2019 - Edin?a Pastro Mendes.pdf: 2588054 bytes, checksum: 87d33da433ee3426cb9cb1ee14afab29 (MD5) Previous issue date: 2019-05-13CAPES - Coordena??o de Aperfei?oamento de Pessoal de N?vel SuperiorCNPq - Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gicoapplication/pdfhttps://tede.ufrrj.br/retrieve/69297/2019%20-%20Edin%c3%a9a%20Pastro%20Mendes.pdf.jpgporUniversidade Federal Rural do Rio de JaneiroPrograma de P?s-Gradua??o em Ci?ncia, Tecnologia e Inova??o em Agropecu?riaUFRRJBrasilPr?-Reitoria de Pesquisa e P?s-Gradua??oALENCAR, J. E.; DIETZE, R. Leishmaniose visceral (Calazar). In: VERONESI, R. Doen?as infecciosas e parasit?rias, 8. ed. Rio de Janeiro: Guanabara Koogan, p. 706-17, 1991. ALIAGA, L. et al. Localized mucosal leishmaniasis due to Leishmania infantum: clinical and microbiologic findings in 31 patients. Medicine (Baltimore), n. 82, p. 147 ?158, 2003. ALMEIDA, O.L.S.; SANTOS, J.B. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review. Anais Brasileiro de Dermatologia, n.3, v. 86, p. 497-506, 2011. ANTINORI, S.; CASCIO, A.; PARRAVICINI, C.; BIANCHI, R.; CORBELLINO, M. Leishmaniasis among organ transplant recipients. Lancet Infectious Diseases, n. 8, p. 191-199, 2008. ARONSON, J.K., Meyler's Side Effects of Drugs: the international encyclopedia of adverse drug reactions and interactions, Elsevier., 15a ed, 2006. ASHFORD, R.W. The leishmaniases as emerging and reemerging zoonoses. International Journal for Parasitology, n. 30, p. 1269-1281, 2000. BASU, N.K., KOLE, L., GHOSH, A., DAS, P.K. Isolation of a nitric oxide synthase from the protozoan parasite Leishmania donovani. FEMS Microbiol. Lett, v.1, n. 156, p. 43-47, 1997. BARBOSA, J.F.; FIGUEIREDO, S.M. DE; MONTEIRO, F.M.; ROCHA-SILVA, F. New Approaches on Leishmaniasis Treatment and Prevention: A Review of Recent Patents. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, v. 9, p. 90?102, 2015. BARRAT, G.; SAINT-PIERRE-CHAZALET, M.; LOISEAU, P.M. Celular Transport and Lipid Interactions of Miltefosine. Current Drug Metabolism, v. 10, n. 3, p. 247-255, 2009. BASSELIN, M.; BADET-DENISOT, M.A.; LAWRENCE, F.; ROBERT-GERO, M. Effects of pentamidine on polyamine level and biosynthesis in wild-type, pentamidine-treated, and pentamidine-resistant Leishmania. Exp Parasitol, v. 85, n. 3, p. 274-282, 1997. BERALDO, H.; GAMBINO, D.; The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini-Reviews in Medicinal Chemistry, v.4, n.1, p. 31-39, 2004. BISUGO, M. C. et al. Assessment of canine visceral leishmaniasis diagnosis by means of a rapid test using recombinant antigen K39 in endemic regions of S?o Paulo state, Brazil. Revista do Instituto Adolfo Lutz, v. 66, n. 2, p. 185-193, 2007. BLANCO,V.M.; COSSIO, A.; MARTINEZ, J.D.; SARAVIA, N.G. Clinical and Epidemiologic Profile of Cutaneous Leishmaniasis in Colombian Children: Considerations for Local Treatment. American Journal of Tropical Medicine and Hygiene, n. 89, p. 359-364, 2013. BOECK, P.; FALC?O, C.A.B.; LEAL, P.C.; YUNES, R.A.; FILHO, V.C.; TORRES-SANTOS, E.C.; ROSSI-BERGMANN, B. Synthesis of chalcone analogues with increased antileishmanial activity, Bioorganic & Medicinal Chemistry, n. 14, p. 1538?1545, 2006. BRAZIL, R.P.; BRAZIL, B.G.; Rangel, E.F.; Lainson, R. Biologia de flebotom?neos neotropicais. Flebotom?neos do Brasil. Editora Fiocruz, Rio de Janeiro, p. 257-274, 2003. BRASIL. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Departamento de Vigil?ncia Epidemiol?gica. Manual de vigil?ncia e controle da leishmaniose visceral. ? 1. ed., 5. reimpr. ? Bras?lia, 2013. BRASIL. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Departamento de Vigil?ncia Epidemiol?gica. Manual de vigil?ncia e controle da leishmaniose visceral. ? 1. ed., 5. reimpr. ? Bras?lia, 2014. BRASIL. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Departamento de Vigil?ncia Epidemiol?gica. Leishmaniose visceral: recomenda??es cl?nicas para redu??o da letalidade. Bras?lia, 2011. BRASIL. Minist?rio da sa?de, Secretaria de vigil?ncia em sa?de. Manual de vigil?ncia e controle da Leishmaniose tegumentar americana. Bras?lia-DF. p. 184, 2007. BRITTINGHAM, A.; MORRISON, C.J.; MCMASTER, W.R.; MCGWIRE, B.S.; CHANG, K.P.; MOSSER, D.M. Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. J Immunol, v. 155, p. 3102-3111, 1995. BURNS-JR, J. M.; SHREFFLER, W.G.; BENSON, D.R.; GHALIB, H.W.; BADARO, R.; REED, S.G. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc. Natl. Acad. Sci. USA, v. 90, n. 2, p. 775?779, 1993. CABREIRA, M.A.A. Ciclo enzo?tico de transmiss?o da Leishmania (Leishmania) chagasi (Cunha e Chagas, 1937) no ec?topo peridom?stico em Barra de Guaratiba, Rio de Janeiro-RJ: estudo de poss?veis vari?veis preditoras. 1999. Disserta??o (Mestrado Sa?de P?blica) ? Escola Nacional de Sa?de P?blica, Funda??o Oswaldo Cruz, Rio de Janeiro, 1999. CABRERA, M.M.; SIMOENS, G.; FALCHI, M.L.; LAVAGGI, O.E., PIRO, E.E.; CASTELLANO, A.; VIDAL, A.; AZQUETA, A.; MONGE, A.L.; DE CER?IN, G.; SAGRERA, G.; SEOANE, H.; CERECETTO, M.; GONZ?LEZ. Bioorg Med Chem, n. 15, v. 10, p. 3356, 2007. CARVALHO, E.M.; CORREA-FILHO, D.; BARCELAR, O.; ALMEIDA, R.P.; LESS, H.; ROCHA, H. Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene, v. 53, p. 273-277, 1995. CARVALHO, P.B.; ARRIBAS, M.A.G.; FERREIRA, E.I. Leishmaniasis: What do we know about its chemotherapy? Braz J Pharm Sci, v. 36, p. 69-96, 2000. CASTRO-PINTO, D.B.; ECHEVARRIA, A.; GENESTRA, M. S; CYSNE-FINKELSTEIN, L.; LEON, L. L. Trypanothione reductase activity is prominent in matacyclic promastigotes and axenic amastigotes of Leishmania amazonensis. Evaluation of its potential as a thepapeutic target. J. Enz. Inhib. Med. Chem., n. 19, p. 57-63, 2004. CASTRO-PINTO, D.B.; GENESTRA, M.; MENEZES, G.B.; WAGHABI, M.; GONCALVES, A.; DE NIGRIS DEL CISTIA, C.; SANT'ANNA, C.M.; LEON, L.L.; MENDON?A-LIMA, L. Cloning and expression of trypanothione reductase from a New World Leishmania species. Arch. Microbiol., v. 189, p. 375-384, 2008. CHAKRABORTY, A.K.; MAJUMDER, H.K. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem Biophys Res Commun, v. 152, n. 2, p. 605-11, 1988. CHAN-BACAB, M.J.; PENA-RODR?GUEZ, L.M. Plant natural products with leishmanial activity. Royal Soc. Chem., n. 18, p. 674-688, 2001. CHAPPUIS, F. et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rew, n. 5, p. 873-882, 2007. CHATTON, J.Y.; BROILLET, M.C. Detection of nitric oxide production by fluorescent indicators. Methods Enzymol., 359, p. 134-48, 2002 CROFT, S.L.; COOMBS, G.H. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol, v. 19, n. 11, p. 502-508, 2003. CROFT, S.L.; SEIFERT, K.; YARDLEY, V. Current scenario of drug development for leishmaniasis. Indian J Med Res, v. 123, n. 3, p. 399-410, 2006. CROFT, S.L.; SUNDAR, S.; FAIRLAMB, AH. Drug resistance in leishmaniasis. Clin Microbiol. Ver, v.19, n.1, p. 111, 2006. CROFT, S.L., YARDLEY, V. Chemotherapy of leishmaniasis. Curr Pharm, v. 8, n. 4, p. 319-342, 2002. CYSNE-FINKELSTEIN, L.; TEMPORAL, R.M.; ALVES, F.A.; LEON, L.L. Leishmania amazonensis: long-term cultivation of axenic amastigotes is associated to metacyclogenesis of promastigotes. Exp Parasitol., v. 89, n.1, p. 58-62, 1998. CUPOLILLO, E.; MEDINA-A.; COSTA, E.; NOYES, H.; MOMEN, H.; GRIMALDI, G.Jr. A revised classifiction for Leishmania and Endotrypanum. Parasitology Today, n. 16, p. 142-144, 2000. DANESHBOD, Y.; ORYAN, A.; DAVARMANESH, M.; SHIRIAN, S.; NEGAHBAN, S.; ALEDAVOOD, A.; DAVARPANAH, M.A.; SOLEIMANPOOR, H.; DANESHBOD, K. Clinical, Histopathologic, and Cytologic Diagnosis of Mucosal Leishmaniasis and Literature Review. Archives of Pathology & Laboratory Medicine, 135, p. 478-482, 2011. DE BRITO M.E.; ANDRADE M.S.; DANTAS-TORRES, F,; RODRIGUES, E.H.; CAVALCANTI, M.P.; de ALMEIDA, A.M.; BRAND?O-FILHO, S.P. Cutaneous leishmaniasis in northeastern Brazil: a critical appraisal of studies conducted in State of Pernambuco. Rev Soc Bras Med Trop., v. 45, n. 4, p. 425-429, 2012. DESJEUX, P.; GHOSH, R.; DHALARIA, P.; STRUB-WOURGAFT, N.; ZIJLSTRA, E.E. Report of the Post Kala-Azar Dermal Leishmaniasis (PKDL) consortium meeting, New Delhi, India, June 2012. Parasites & Vectors, n. 6, p. 27-29, 2013. DESJEUX, P. Leishmaniasis: current situation and new perspectives. Comp Immunol, Microbiol Infect Dis., n. 27, p. 305?318, 2004. DETSI, A.; MAJDALANI, M.; KONTOGIORGIS, C. A.; HADJIPAVLOU-LITINA, D.; KEFALAS, P. Bioorg. Med. Chem., v. 17, n. 23, p. 8073-8085, 2009. ELLMAN, G.L.; COURTNEY, K.D.; ANDRES, V.; FEATHERSTONE, R.M. Biochemical pharmacology, v. 7, n.2, p. 88-95, 1961. FAILLI, P.; NISTRI, S.; QUATTRONE, S.; MAZZETTI, L.; BIGAZZI, M.; SACCHI, T.B. et al. Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells. FASEB J., n. 16, p. 252?254, 2002. FEITOSA, M. M. et al. Aspectos cl?nicos de c?es com leishmaniose visceral no munic?pio de Ara?atuba- S?o Paulo (Brasil). Cl?nVet., v. 5, n. 28, p. 36-44, 2000. FISCHER, D.C.H. Antiprotozoal activity of Brazilian plant extracts from isoquinoline alkaloidsproducing families. Phytomedicine, v. 12, p. 382-390, 2005. FRAGA, J.; VELAND, N.; MONTALVO, A.M.; PRAET, N.; BOGGILD, A.K.; VALENCIA, B.M.; AR?VALO, J.; LLANOS-CUENTAS, A.; DUJARDIN, J.C.; VAN DER AUWERA, G. Accurate and rapid species typing from cutaneous and mucocutaneous leishmaniasis lesions of the New World. Diagn Microbiol Infect Dis., v. 74, n. 2, p. 142-150, 2012. FRANCO, M.A.; BARBOSA, A.C.; RATH, S.; DOREA, J.G. Antimony oxidation states in antileishmanial drugs. Am J Trop Med Hyg, n. 52, v. 5, p. 435-437, 1995. FR?ZARD, F.; DEMICHELI, C.; RIBEIRO, R. Pentavalent antimonials: new perspectives for old drugs. Molecules, n. 14, p. 2317, 2009. GONTIJO, C.M.F.; MELO, M.N. Leishmaniose Visceral no Brasil: quadro atual, desafios e perspectivas. Rev bras epidemiol, v. 7, n. 3, p. 338?349, 2004. GONTIJO, B; CARVALHO. M.L.R. Leishmaniose Tegumentar Americana. Rev Soc Brasil Medic Trop., n. 36, v.1, p. 71-80, 2003. GOTO, H.; LINDOSO, J.A.L. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther, v. 8, n. 4, p. 419-43, 2010. GOULART, C.M. S?ntese e Avalia??o da Atividade Anticorrosiva de Tiossemicarbazonas, Chalconas-tiossemicarbazonas e 1-Tiocarbamoil-4,5-diidropiraz?is. 2015. Tese (Doutorado em Qu?mica) - Universidade Federal Rural do Rio de Janeiro, Rio de Janeiro, 2015. GRIMALDI Jr., G.; TESH, R.B. Leishmaniasis of the New World: current concepts and implications for future research. Clin Microb Rev., v. 6, p. 230?250, 1993. GREEN, L.C.; WAGNER, D.A.; GLOGOWSKI, J.; SKIPPER, P.L.; WISHNOK, J.S.; TANNENBAUM, S.R. Analysis of nitrate, nitrite, and [15 N] nitrate in biological fluids. Analytical Biochemistry, n. 126, p.131-138, 1982. GUERRA, J.A.; PRESTES, S.R.; SILVEIRA, H.; COELHO, L.I.; GAMA, P.; MOURA, A.; AMATO, V.; BARBOSA, M. D.; FERREIRA, L.C. Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis; v. 5, n. 3, p. 980, 2011. HAMILTON, C. J. et al. Ellman's-reagent-mediated regeneration of trypnothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. Biochem. J., v. 369, p. 529-537, 2003. JHA, T.K.; SUNDAR, S.; THAKUR, C.P.; BACHMANN, P.; KARBWANG, J.; FISCHER, C.; VOSS, A.; BERMAN, J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med, v. 341, n. 24, p. 1795-1800, 1999. JOHNSTONE, A.; THORPE, R. lmmunochemistry in Practice, Blackwell. Scientific Publications. 1982. KUMAR, N.; CHAUHAN, A; DRABU, S. Biomed. Pharmacother. v. 65, n. 5, p. 375-380, 2011. LUO, Y.; SONG, R.; LI, Y.; ZHANG, S.; LIU, Z.; FU, J.; ZHU, H. Bioorganic & Medicinal Chemistry Letters. v. 22, n. 9, p. 3039-3043, 2012 MARSDEN, P.D. Mucosal leishmaniasis (Espundia Escomel,1911). Transactions of the Royal Society of Tropical Medicine and Hygiene, v. 80, p. 859-876, 1986. MARZOCHI, M.C.A.; TEIXEIRA, P.C.; MARZOCHI, K.B.F.; CONCEI??O, N.F.; COUTINHO, W.; BRITO, D.B. Vacuum aspiratory puncture system for Leishmania culturing, isolation and transport. Preliminary report. Rev. Inst. Med. Trop. S?o Paulo, v. 35, p. 301-303, 1993. MARZOCHI, M.C.A. Doen?as infecto-parasit?rias: Leishmanioses no Brasil: as leishmanioses tegumentares. J Bras Med., v.63, p. 82-104, 1992. MARZOCHI, M.C.; MARZOCHI, K.B.F. Tegumentary and visceral leishmaniasis in Brazil: emerging anthropozoonosis and for their control. Cadernos de Sa?de P?blica n. 10, v. 2, p. 359-375, 1994. MELOS, J.L.R.; TORRES-SANTOS, E.C.; FAI?ES, V.S.; CATARINA DE NIGRIS DEL CISTIA , C.N.D.; SANT'ANNA, C.M.R.; RODRIGUES-SANTOS, C.E.; ECHEVARRIA, A. Novel 3,4-methylenedioxyde-6-X-benzaldehyde-thiosemicarbazones: Synthesis and antileishmanial effects against Leishmania amazonensis. European Journal of Medicinal Chemistry, n. 103, p. 409 e 417, 2015. MELLO, M.V.P. et al. A comprehensive review of chalcone derivatives as antileishmanial agentes. European Journal of Medicinal Chemistry, v. 150, p. 920-929, 2018. MENDON?A-FILHO, R.R.; RODRIGUES, I. A.; ALVIANO, D.S.; SANTOS, L.S.; SOARES, R.M.A.; ALVIANO, C.S.; LOPES, A.H.C.S.; ROSA, M.S.S. Leishmanicidal activity of polyphenolic-rich extract from husk fiber of Cocos nicifera Linn. (Palmae). Rev. Microbiol., v. 155, p.136-143, 2004. MONDAL, R.; GUPTA, A. D.; MALLIK, A. K. Tetrahedron Lett., v. 52, n. 39, p. 5020-5024, 2011. MONZOTE, L.; STAMBERG, W.; PATEL, A.; ROSENAU, T.; MAES, L.; COS, P.; GILLE, L. Current Treatment of Leishmaniasis: A sand flies. International Journal for Parasitology, n. 37, p. 1097, 2007. MORENO, S. N. J.; CARNIERI. E. G. S.; DOCAMPO, R. Inhibition of Trypanossoma cruzi trypanothione reductase by crystal violet. Mol Biochem Parasitol., v. 67, p. 313- 320, 1994. M?LLER, S.; LIEBAU, E.; ROLF, D.W.; KRAUTH-SIEGEL, R.L. Thiol-based redox metabolism of protozoan parasites. Trends in Parasitology, v. 19, n. 7, p. 320-328, 2003. MURRAY, H.W.; BERMAN, J.D.; DAVIES, C.R.; SARAVIA, N.G. Advances in leishmaniasis. Lancet, n. 366, p. 1561-1577, 2005 MYLER, P.J.; FASEL, N. Leishmaniasis: epidemiological Trends and Diagnosis. Leishmania - After the genome, p. 1-14, 2008. HEBY, O.; PERSSON, L.; RENTALA, M. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas? disease, and leishmaniasis. Amino Acids, v. 33, n. 2, p. 359-366, 2007. NAGLE, A.S.; KHARE, S.; KUMAR, A.B.; SUPEK, F.; BUCHYNSKYY, A.; MATHISON, C.J.N.; MOLTENI, V. Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chemical Reviews, n. 114, p. 11305, 2014. NEUBER, H. Leishmaniasis. Journal der Deutschen Dermatologischen Gesellschaft, n. 6, p. 754-764, 2008. NOGUEIRA, Y.L.; ODORIZZI, R.M.; NAKAMURA, P.M.A. Comparison of the immune parameters of dogs infected with visceral leishmaniasis using Western blot and neutralization techniques. Rev Inst Med Trop., S?o Paulo, v. 49, n. 6, p. 379-384, 2007. OLIVEIRA, L.F.; SCHUBACH, A.O.; MARTINS, M.M.; PASSOS, S.L.; OLIVEIRA, R.V.; MARZOCHI, M.C.; ANDRADE, C.A. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica, 118, p. 87-96, 2011. ORGANIZACION MUNDIAL DE LA SALUD ? Lucha contra las leishmaniasis. Ginebra, OMS, (S?rie de Informes T?cnicos, 793) 178p.1990. ORGANIZA??O MUNDIAL DE SA?DE (OMS). Temas de Salud- Leishmaniasis. 2012. Dispon?vel em: < http://www.who.int/leishmaniasis/en/> Acesso em: 24 mar de 2017. ORGANIZA??O PAN-AMERICANA DA SA?DE: Leishmanioses: Informe Epidemiol?gico das Am?ricas: Washington: Organiza??o Pan-Americana da Sa?de; 2018. Dispon?vel em www.paho.org/leishmaniasis ?ZDEMIR, A.; ALTINTOP, M.D.; TURAN-ZITOUNI, G.; ?IFT?I, G.A.; ERTORUN, I.; ALATAS, ?.; KAPLANCICLI, Z.A. Synthesis and Evaluation of New Indole-Based Chalcones as Potential Antiinflammatory Agents, European Journal of Medicinal Chemistry, n. 89, p. 304, 2015. PALATNICK DE SOUSA, C.B. et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg, v. 65, n. 5, p. 510-517, 2001. PENNA, H. A. Leishmaniose visceral no Brasil. Brasil-M?dico, v. 48, p. 949-950, 1934. PESSOA, S.B. Parasitologia M?dica. 11. ed., Rio de Janeiro: Guanabara Koogan; 1982. PIMENTEL, M.I.F.; BAPTISTA, C.; RUBIN, E.F.; VASCONCELLOS, E.F.; LYRA, M.R.; SALGUEIRO, M.M. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report. Rev Soc Bras Med Trop., n. 44, p. 254, 2011. PISCOPO, T.V.; MALLIA, A.C. Leishmaniasis. Postgrad Med J, v. 82, n. 972, p.649-657, 2006. POCAI, E.A. et al. Leishmaniose visceral (calazar). Cinco casos em Santa Maria, Rio Grande do Sul, Brasil. Ci?nc Rural, v. 28, n. 3, p. 501-505, 1998. RANI, M.; YUSUF, M; KHAN, S. J. Saudi Chem. Soc., n. 16, p. 431, 2012. REY, L. Bases da Parasitologia M?dica, 2? ed. Ed. Guanabara Koogan, Rio de Janeiro, p. 349, 2001. RIGOL, C.; OLEA-AZAR, C.; MENDIZ?BAL, F.; OTERO, L.; AMBINO, D.; GONZ?LEZ, M.; CERECETTO, H. Electrochemical and ESR study of 5-nitrofuryl-containing thiosemicarbazones antiprotozoal drugs. Spectrochimica Acta, Part A., v. 61, n. 13-14, p. 2933-2938, 2005. SANTOS, D.O.; COUTINHO, C.E.R.; MADEIRA, M.F.; BOTTINO, C.G.; VIEIRA, R.T.; NASCIMENTO, S.B.; BERNARDINO, A.; BOURGUIGNON, S.C.; CORTE-REAL, S.; Pinho, R.T.; RODRIGUES, C.R.; CASTRO, H.C. Leishmaniasis treatment-a challenge that remains: a review. Parasitol. Res., v. 103, p. 1?10, 2008. SANTOS, M. et al. Riboflavin biosynthesis in Saccharomyces cerevisiae. Cloning, characterization, and expression of the RIB5 gene encoding riboflavin synthase. J Biol Chem, v. 270, n. 1, p. 437-44, 1995. SANTOS, S.O. et al. Incrimination of Lutzomyia cruzi as a vector of American Visceral Leishmaniasis. Medical and Veterinary Entomology, n. 2, p. 315-317, 1998. SCARIM, C.B. et al. Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. European Journal of Medicinal Chemistry, n. 162, p. 378-395, 2019. SHAW, J. J. Further thoughts on the use of the name Leishmania (Leishmania) infantum chagasi for the aetiological agent of American visceral leishmaniasis. Mem?rias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 101, n. 5, p. 577-579, 2006. SILVA, A.C. et al. Aryl thiosemicarbazones: in vitro and immunomodulatory activities against L. amazonensis. Exp. Parasitol., n. 177, p. 57-65, 2017. SILVA, F.S. Patologia e patog?nese da leishmaniose visceral canina. Revista Tr?pica ? Ci?ncias Agr?rias e Biol?gicas, v. 1, n. 1, p. 20-31, 2007. SINGH, S.; SIVAKUMAR, R. Challenges and new discoveries in the treatment of leishmaniasis. J Inf Chemother, v. 10, n. 6, p. 307-315, 2004. SisLeish-OPAS/OMS: Dados reportados pelos Programas Nacionais de Leishmanioses/Servi?os de Vigil?ncia. Acesso em: 01 de Dezembro de 2017. SOARES, R.O.A.; ECHEVARRIA, A.; BELLIENY, M.S.S.; PINHO, R.T.; DE LEO, R.M.M.; SEGUINS, W.S.; MACHADO, G.M.; CANTO-CAVALHEIRO, M.M.; LEON, L.L. Evaluation of thiosemicarbazones and semicarbazones as potential agents anti-Trypanosoma cruzi. Experimental Parasitology, n. 129, p. 381?387, 2011. STRAZZULLA, A.; COCUZZA, S.; PINZONE, M. R.; POSTORINO, M.C.; COSENTINO, S.; SERRA, A.; CACOPARDO, B.; NUNNARI, G. Mucosal Leishmaniasis: An Underestimated Presentation of a Neglected Disease. Biomed Research International, 2013. STUART, K.; BRUN,R.; CROFT, S.; FAIRLAMB, A.; GURTLER, R.E.; McKERROW, J., REED, S.; TARLETON, R. Kinetoplastids: related protozoan pathogens, different diseases. Journal of Clinical Investigation; v. 118, n. 4, p. 1301-1310, 2008. SUNDAR, S.; CHAKRAVARTY, J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs, v. 17, n. 5, p. 787-794, 2008. TAJUDDEEN, N.; ISAH M.B.; SULEIMAN M.A.; van HEERDEN F.R.; IBRAHIM M.A. The chemotherapeutic potential of chalcones against leishmaniases: a review. Int J Antimicrob Agents., n. 51, v. 3, p. 311-318, 2018. TEMPONE, A.G.; BORBOREMA, S.E.T.; ANDRADE Jr, H.F.; GUALDA, N.C.A.; YOGI, A.; CRAVALHO, C.S.; BACHIEGA, D.; LUPO, F.N.; BONOTTO, S.V.; FISCHER, D.C.H. Antiprotozoal activity of Brazilian plant extracts from isoquinoline alkaloidsproducing families. Phytomedicine, v.12, p. 382-390, 2005. Tuon, F.F.; Amato, V.S.; Graf, M.E.; Siqueira, A.M.; Nicodemo, A.C.; Neto, V.A. Treatment of New World cutaneous leishmaniasis ? a systematic review with a meta-analysis. Int J Dermatol, v. 4, n. 2, p. 109-124, 2008. van GRIENSVEN, J.; DIRO, E. Visceral Leishmaniasis. Infectious Disease Clinics of North America, v. 26, p. 309, 2012. ORGANIZA??O MUNDIAL DE SA?DE (OMS). Temas de Salud- Leishmaniasis. 2012. Dispon?vel em: < http://www.who.int/leishmaniasis/en/> Acesso em: 24 mar de 2017. World Health Organization (WHO) 2013. http://apps.who.int/tdr/publications/tdr-image-library?idNumber=00061046. Acessado em 30 de julho de 2017. World Health Organization 2010 (OMS/WHO). http://apps.who.int/tdr/publications/tdr-image-library?idNumber=00061043. Acessado em 5 de Agosto de 2017. World Health Organization (WHO), 2015. 1-164p. WHO 2010a. Technical Report Series. Control of the leishmaniases. Dispon?vel em: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. Acesso em 10 de fevereiro de 2017. WHO 2010b. World Health Organization. First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases. Dispon?vel em: http://www.who.int/neglected_diseases/2010report/en/. Acesso em 20 de novembro de 2017. WHO 2012. Second WHO Report on Neglected Tropical Diseases.Treatment recommendation for leishmaniasis. Dispon?vel em: http:// www.who.int/leishmaniases/research/978924129496_pp67_71.pdf?ua=1. Acesso em 20 de abril de 2017. WHO - World Health Organization, 2019. Dispon?vel em: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis (14 de mar?o de 2019). WYLLIE, S.; CUNNINGHAM, M.L.; FAIRLAMB, A.H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem, v. 279, n. 38, p. 39925-39932, 2004. ZAVERUCHA, T.V. Vacina??o murina com fra??es subcelulares de Leishmania amazonensis sob modula??o de Mycobacterium bovis BCG e ciclofosfamida. 2005. Tese (Doutorado em Biologia Parasit?ria) Instituto Oswaldo Cruz, Funda??o Oswaldo Cruz, Rio de Janeiro, 2005.LeishmaniosesChalconasTiossemicarbazonasLeishmaniosisChalconesThiosemicarbazonesBioqu?micaParasitologiaInvestiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonasInvestigation of in vitro antileishmanial activity of chalcones-thiosemicarbazonesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFRRJinstname:Universidade Federal Rural do Rio de Janeiro (UFRRJ)instacron:UFRRJTHUMBNAIL2019 - Edin?a Pastro Mendes.pdf.jpg2019 - Edin?a Pastro Mendes.pdf.jpgimage/jpeg1943http://localhost:8080/tede/bitstream/jspui/5651/4/2019+-+Edin%C3%A9a+Pastro+Mendes.pdf.jpgcc73c4c239a4c332d642ba1e7c7a9fb2MD54TEXT2019 - Edin?a Pastro Mendes.pdf.txt2019 - Edin?a Pastro Mendes.pdf.txttext/plain202703http://localhost:8080/tede/bitstream/jspui/5651/3/2019+-+Edin%C3%A9a+Pastro+Mendes.pdf.txt9b114330abf45affc0434ecac00917c5MD53ORIGINAL2019 - Edin?a Pastro Mendes.pdf2019 - Edin?a Pastro Mendes.pdfapplication/pdf2588054http://localhost:8080/tede/bitstream/jspui/5651/2/2019+-+Edin%C3%A9a+Pastro+Mendes.pdf87d33da433ee3426cb9cb1ee14afab29MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82089http://localhost:8080/tede/bitstream/jspui/5651/1/license.txt7b5ba3d2445355f386edab96125d42b7MD51jspui/56512022-05-13 01:01:18.131oai:localhost: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Biblioteca Digital de Teses e Dissertaçõeshttps://tede.ufrrj.br/PUBhttps://tede.ufrrj.br/oai/requestbibliot@ufrrj.br||bibliot@ufrrj.bropendoar:2022-05-13T04:01:18Biblioteca Digital de Teses e Dissertações da UFRRJ - Universidade Federal Rural do Rio de Janeiro (UFRRJ)false
dc.title.por.fl_str_mv Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas
dc.title.alternative.eng.fl_str_mv Investigation of in vitro antileishmanial activity of chalcones-thiosemicarbazones
title Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas
spellingShingle Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas
Mendes, Edin?a Pastro
Leishmanioses
Chalconas
Tiossemicarbazonas
Leishmaniosis
Chalcones
Thiosemicarbazones
Bioqu?mica
Parasitologia
title_short Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas
title_full Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas
title_fullStr Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas
title_full_unstemmed Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas
title_sort Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas
author Mendes, Edin?a Pastro
author_facet Mendes, Edin?a Pastro
author_role author
dc.contributor.advisor1.fl_str_mv Echevarria, Aurea
dc.contributor.advisor1ID.fl_str_mv CPF: 668.742.388-68
dc.contributor.advisor-co1.fl_str_mv Cavalheiro, Marilene Marcuzzo do Canto
dc.contributor.advisor-co1ID.fl_str_mv CPF: 175.087.030-49
dc.contributor.referee1.fl_str_mv Echevarria, Aurea
dc.contributor.referee2.fl_str_mv Santos, Eduardo Caio Torres dos
dc.contributor.referee3.fl_str_mv Santos, Fernanda Nunes
dc.contributor.referee4.fl_str_mv Silva, Lucia Helena Pinto da
dc.contributor.referee5.fl_str_mv Coelho, Irene da Silva
dc.contributor.authorID.fl_str_mv CPF: 706.903.407-53
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/6931787630199061
dc.contributor.author.fl_str_mv Mendes, Edin?a Pastro
contributor_str_mv Echevarria, Aurea
Cavalheiro, Marilene Marcuzzo do Canto
Echevarria, Aurea
Santos, Eduardo Caio Torres dos
Santos, Fernanda Nunes
Silva, Lucia Helena Pinto da
Coelho, Irene da Silva
dc.subject.por.fl_str_mv Leishmanioses
Chalconas
Tiossemicarbazonas
topic Leishmanioses
Chalconas
Tiossemicarbazonas
Leishmaniosis
Chalcones
Thiosemicarbazones
Bioqu?mica
Parasitologia
dc.subject.eng.fl_str_mv Leishmaniosis
Chalcones
Thiosemicarbazones
dc.subject.cnpq.fl_str_mv Bioqu?mica
Parasitologia
description The leishmaniosis are a serious global public health problem, affecting patients with pronounced deformity, morbidity and mortality, as well as difficulty of access and adherence to treatment, lack of investment in the development of new drugs by pharmaceutical industry and inefficient social policies. The treatment used is not adequate due to drug effectiveness and toxicity. Additionally, resistance to available drugs has been shown by the sensitivity of several strains to these substances and treatment can be long and require hospitalization. In an attempt to find new anti-parasitic agents that can help with Leishmaniosis treatment, a series of seven chalcones-thiosemicarbazones with different substituents (CT-H, CT-Me, CT-CN, CT-F, CT-Br, CT-Cl and CT-NO2) against the promastigote forms of parasites of Leishmania spp was assessed. Evaluation started through the screening of different substances at 50?M concentration with promastigote forms of L. amazonensis, and when leishmanicidal activity was observed, a further evaluation with L. amazonensis, L. infantum and L. braziliensis was performed in the form of promastigotes at concentration range of 50 to 1.56 ?M dissolved in DMSO. Parasite cultures were prepared with Schneider?s medium supplemented with 10% or 20% of bovine fetal serum, arranged in 96 wells microplates and incubated at 26? C for 12 h. All trials were conducted in triplicate in three independent assays and pentamidine was used as positive control. The cytotoxicity of these compounds was assessed in uninfected cells with murine peritoneal macrophages in 24 h presenting LD50 values (?M) for CT-Br and CT-Cl 44.24 and 32.75 ?M respectively, demonstrating that those compounds are less cytotoxic than pentamidine whose value was = 8.5 . The promastigate forms were cultivated with and without these substances in Schneider?s culture medium and incubated at the 26? C for 12 hours using pentamidine isethionate as a reference drug. After incubation, the viability of the parasites was determined by using the MTT assay. The results showed that the CT-Cl was the most active compound for the three species tested, presenting IC50 = 5.22 ?M to L. amazonensis, 3.97 ?M to L. infantum and 3.89 ?M to L. braziliensis, respectively. Pentamidine presented IC50 = 5.20 ?M. The other compounds also obtained good results with IC50 in the range of 4.34 to 14.80 ?M. In trials of CT with the L. amazonensis axenic amastigotes IC50 values were obtained in the range of 6.18 to 14.74 ?M, indicating very interesting activity. This study also investigated the mechanism of action of most active substances in trypanothione reductase enzyme and the NO synthase pathways by evaluating nitric oxide. However, positive results were not observed to support those pathways as significant to chalcones-thiosemicarbazones action. The results obtained by the evaluation of chalcones-thiosemicarbazones action on the three species indicate this class of substances as potential antileishmanial agents.
publishDate 2019
dc.date.issued.fl_str_mv 2019-05-13
dc.date.accessioned.fl_str_mv 2022-05-12T20:53:53Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv MENDES, Edin?a Pastro. Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas. 2019. 73 f. Tese (Doutorado em Ci?ncia, Tecnologia e Inova??o Agropecu?ria) - Pr?-Reitoria de Pesquisa e P?s-Gradua??o, Universidade Federal Rural do Rio de Janeiro, Serop?dica, RJ, 2019.
dc.identifier.uri.fl_str_mv https://tede.ufrrj.br/jspui/handle/jspui/5651
identifier_str_mv MENDES, Edin?a Pastro. Investiga??o da atividade antileishmania in vitro de chalconas-tiossemicarbazonas. 2019. 73 f. Tese (Doutorado em Ci?ncia, Tecnologia e Inova??o Agropecu?ria) - Pr?-Reitoria de Pesquisa e P?s-Gradua??o, Universidade Federal Rural do Rio de Janeiro, Serop?dica, RJ, 2019.
url https://tede.ufrrj.br/jspui/handle/jspui/5651
dc.language.iso.fl_str_mv por
language por
dc.relation.references.por.fl_str_mv ALENCAR, J. E.; DIETZE, R. Leishmaniose visceral (Calazar). In: VERONESI, R. Doen?as infecciosas e parasit?rias, 8. ed. Rio de Janeiro: Guanabara Koogan, p. 706-17, 1991. ALIAGA, L. et al. Localized mucosal leishmaniasis due to Leishmania infantum: clinical and microbiologic findings in 31 patients. Medicine (Baltimore), n. 82, p. 147 ?158, 2003. ALMEIDA, O.L.S.; SANTOS, J.B. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review. Anais Brasileiro de Dermatologia, n.3, v. 86, p. 497-506, 2011. ANTINORI, S.; CASCIO, A.; PARRAVICINI, C.; BIANCHI, R.; CORBELLINO, M. Leishmaniasis among organ transplant recipients. Lancet Infectious Diseases, n. 8, p. 191-199, 2008. ARONSON, J.K., Meyler's Side Effects of Drugs: the international encyclopedia of adverse drug reactions and interactions, Elsevier., 15a ed, 2006. ASHFORD, R.W. The leishmaniases as emerging and reemerging zoonoses. International Journal for Parasitology, n. 30, p. 1269-1281, 2000. BASU, N.K., KOLE, L., GHOSH, A., DAS, P.K. Isolation of a nitric oxide synthase from the protozoan parasite Leishmania donovani. FEMS Microbiol. Lett, v.1, n. 156, p. 43-47, 1997. BARBOSA, J.F.; FIGUEIREDO, S.M. DE; MONTEIRO, F.M.; ROCHA-SILVA, F. New Approaches on Leishmaniasis Treatment and Prevention: A Review of Recent Patents. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, v. 9, p. 90?102, 2015. BARRAT, G.; SAINT-PIERRE-CHAZALET, M.; LOISEAU, P.M. Celular Transport and Lipid Interactions of Miltefosine. Current Drug Metabolism, v. 10, n. 3, p. 247-255, 2009. BASSELIN, M.; BADET-DENISOT, M.A.; LAWRENCE, F.; ROBERT-GERO, M. Effects of pentamidine on polyamine level and biosynthesis in wild-type, pentamidine-treated, and pentamidine-resistant Leishmania. Exp Parasitol, v. 85, n. 3, p. 274-282, 1997. BERALDO, H.; GAMBINO, D.; The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini-Reviews in Medicinal Chemistry, v.4, n.1, p. 31-39, 2004. BISUGO, M. C. et al. Assessment of canine visceral leishmaniasis diagnosis by means of a rapid test using recombinant antigen K39 in endemic regions of S?o Paulo state, Brazil. Revista do Instituto Adolfo Lutz, v. 66, n. 2, p. 185-193, 2007. BLANCO,V.M.; COSSIO, A.; MARTINEZ, J.D.; SARAVIA, N.G. Clinical and Epidemiologic Profile of Cutaneous Leishmaniasis in Colombian Children: Considerations for Local Treatment. American Journal of Tropical Medicine and Hygiene, n. 89, p. 359-364, 2013. BOECK, P.; FALC?O, C.A.B.; LEAL, P.C.; YUNES, R.A.; FILHO, V.C.; TORRES-SANTOS, E.C.; ROSSI-BERGMANN, B. Synthesis of chalcone analogues with increased antileishmanial activity, Bioorganic & Medicinal Chemistry, n. 14, p. 1538?1545, 2006. BRAZIL, R.P.; BRAZIL, B.G.; Rangel, E.F.; Lainson, R. Biologia de flebotom?neos neotropicais. Flebotom?neos do Brasil. Editora Fiocruz, Rio de Janeiro, p. 257-274, 2003. BRASIL. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Departamento de Vigil?ncia Epidemiol?gica. Manual de vigil?ncia e controle da leishmaniose visceral. ? 1. ed., 5. reimpr. ? Bras?lia, 2013. BRASIL. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Departamento de Vigil?ncia Epidemiol?gica. Manual de vigil?ncia e controle da leishmaniose visceral. ? 1. ed., 5. reimpr. ? Bras?lia, 2014. BRASIL. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Departamento de Vigil?ncia Epidemiol?gica. Leishmaniose visceral: recomenda??es cl?nicas para redu??o da letalidade. Bras?lia, 2011. BRASIL. Minist?rio da sa?de, Secretaria de vigil?ncia em sa?de. Manual de vigil?ncia e controle da Leishmaniose tegumentar americana. Bras?lia-DF. p. 184, 2007. BRITTINGHAM, A.; MORRISON, C.J.; MCMASTER, W.R.; MCGWIRE, B.S.; CHANG, K.P.; MOSSER, D.M. Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. J Immunol, v. 155, p. 3102-3111, 1995. BURNS-JR, J. M.; SHREFFLER, W.G.; BENSON, D.R.; GHALIB, H.W.; BADARO, R.; REED, S.G. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc. Natl. Acad. Sci. USA, v. 90, n. 2, p. 775?779, 1993. CABREIRA, M.A.A. Ciclo enzo?tico de transmiss?o da Leishmania (Leishmania) chagasi (Cunha e Chagas, 1937) no ec?topo peridom?stico em Barra de Guaratiba, Rio de Janeiro-RJ: estudo de poss?veis vari?veis preditoras. 1999. Disserta??o (Mestrado Sa?de P?blica) ? Escola Nacional de Sa?de P?blica, Funda??o Oswaldo Cruz, Rio de Janeiro, 1999. CABRERA, M.M.; SIMOENS, G.; FALCHI, M.L.; LAVAGGI, O.E., PIRO, E.E.; CASTELLANO, A.; VIDAL, A.; AZQUETA, A.; MONGE, A.L.; DE CER?IN, G.; SAGRERA, G.; SEOANE, H.; CERECETTO, M.; GONZ?LEZ. Bioorg Med Chem, n. 15, v. 10, p. 3356, 2007. CARVALHO, E.M.; CORREA-FILHO, D.; BARCELAR, O.; ALMEIDA, R.P.; LESS, H.; ROCHA, H. Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene, v. 53, p. 273-277, 1995. CARVALHO, P.B.; ARRIBAS, M.A.G.; FERREIRA, E.I. Leishmaniasis: What do we know about its chemotherapy? Braz J Pharm Sci, v. 36, p. 69-96, 2000. CASTRO-PINTO, D.B.; ECHEVARRIA, A.; GENESTRA, M. S; CYSNE-FINKELSTEIN, L.; LEON, L. L. Trypanothione reductase activity is prominent in matacyclic promastigotes and axenic amastigotes of Leishmania amazonensis. Evaluation of its potential as a thepapeutic target. J. Enz. Inhib. Med. Chem., n. 19, p. 57-63, 2004. CASTRO-PINTO, D.B.; GENESTRA, M.; MENEZES, G.B.; WAGHABI, M.; GONCALVES, A.; DE NIGRIS DEL CISTIA, C.; SANT'ANNA, C.M.; LEON, L.L.; MENDON?A-LIMA, L. Cloning and expression of trypanothione reductase from a New World Leishmania species. Arch. Microbiol., v. 189, p. 375-384, 2008. CHAKRABORTY, A.K.; MAJUMDER, H.K. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem Biophys Res Commun, v. 152, n. 2, p. 605-11, 1988. CHAN-BACAB, M.J.; PENA-RODR?GUEZ, L.M. Plant natural products with leishmanial activity. Royal Soc. Chem., n. 18, p. 674-688, 2001. CHAPPUIS, F. et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rew, n. 5, p. 873-882, 2007. CHATTON, J.Y.; BROILLET, M.C. Detection of nitric oxide production by fluorescent indicators. Methods Enzymol., 359, p. 134-48, 2002 CROFT, S.L.; COOMBS, G.H. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol, v. 19, n. 11, p. 502-508, 2003. CROFT, S.L.; SEIFERT, K.; YARDLEY, V. Current scenario of drug development for leishmaniasis. Indian J Med Res, v. 123, n. 3, p. 399-410, 2006. CROFT, S.L.; SUNDAR, S.; FAIRLAMB, AH. Drug resistance in leishmaniasis. Clin Microbiol. Ver, v.19, n.1, p. 111, 2006. CROFT, S.L., YARDLEY, V. Chemotherapy of leishmaniasis. Curr Pharm, v. 8, n. 4, p. 319-342, 2002. CYSNE-FINKELSTEIN, L.; TEMPORAL, R.M.; ALVES, F.A.; LEON, L.L. Leishmania amazonensis: long-term cultivation of axenic amastigotes is associated to metacyclogenesis of promastigotes. Exp Parasitol., v. 89, n.1, p. 58-62, 1998. CUPOLILLO, E.; MEDINA-A.; COSTA, E.; NOYES, H.; MOMEN, H.; GRIMALDI, G.Jr. A revised classifiction for Leishmania and Endotrypanum. Parasitology Today, n. 16, p. 142-144, 2000. DANESHBOD, Y.; ORYAN, A.; DAVARMANESH, M.; SHIRIAN, S.; NEGAHBAN, S.; ALEDAVOOD, A.; DAVARPANAH, M.A.; SOLEIMANPOOR, H.; DANESHBOD, K. Clinical, Histopathologic, and Cytologic Diagnosis of Mucosal Leishmaniasis and Literature Review. Archives of Pathology & Laboratory Medicine, 135, p. 478-482, 2011. DE BRITO M.E.; ANDRADE M.S.; DANTAS-TORRES, F,; RODRIGUES, E.H.; CAVALCANTI, M.P.; de ALMEIDA, A.M.; BRAND?O-FILHO, S.P. Cutaneous leishmaniasis in northeastern Brazil: a critical appraisal of studies conducted in State of Pernambuco. Rev Soc Bras Med Trop., v. 45, n. 4, p. 425-429, 2012. DESJEUX, P.; GHOSH, R.; DHALARIA, P.; STRUB-WOURGAFT, N.; ZIJLSTRA, E.E. Report of the Post Kala-Azar Dermal Leishmaniasis (PKDL) consortium meeting, New Delhi, India, June 2012. Parasites & Vectors, n. 6, p. 27-29, 2013. DESJEUX, P. Leishmaniasis: current situation and new perspectives. Comp Immunol, Microbiol Infect Dis., n. 27, p. 305?318, 2004. DETSI, A.; MAJDALANI, M.; KONTOGIORGIS, C. A.; HADJIPAVLOU-LITINA, D.; KEFALAS, P. Bioorg. Med. Chem., v. 17, n. 23, p. 8073-8085, 2009. ELLMAN, G.L.; COURTNEY, K.D.; ANDRES, V.; FEATHERSTONE, R.M. Biochemical pharmacology, v. 7, n.2, p. 88-95, 1961. FAILLI, P.; NISTRI, S.; QUATTRONE, S.; MAZZETTI, L.; BIGAZZI, M.; SACCHI, T.B. et al. Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells. FASEB J., n. 16, p. 252?254, 2002. FEITOSA, M. M. et al. Aspectos cl?nicos de c?es com leishmaniose visceral no munic?pio de Ara?atuba- S?o Paulo (Brasil). Cl?nVet., v. 5, n. 28, p. 36-44, 2000. FISCHER, D.C.H. Antiprotozoal activity of Brazilian plant extracts from isoquinoline alkaloidsproducing families. Phytomedicine, v. 12, p. 382-390, 2005. FRAGA, J.; VELAND, N.; MONTALVO, A.M.; PRAET, N.; BOGGILD, A.K.; VALENCIA, B.M.; AR?VALO, J.; LLANOS-CUENTAS, A.; DUJARDIN, J.C.; VAN DER AUWERA, G. Accurate and rapid species typing from cutaneous and mucocutaneous leishmaniasis lesions of the New World. Diagn Microbiol Infect Dis., v. 74, n. 2, p. 142-150, 2012. FRANCO, M.A.; BARBOSA, A.C.; RATH, S.; DOREA, J.G. Antimony oxidation states in antileishmanial drugs. Am J Trop Med Hyg, n. 52, v. 5, p. 435-437, 1995. FR?ZARD, F.; DEMICHELI, C.; RIBEIRO, R. Pentavalent antimonials: new perspectives for old drugs. Molecules, n. 14, p. 2317, 2009. GONTIJO, C.M.F.; MELO, M.N. Leishmaniose Visceral no Brasil: quadro atual, desafios e perspectivas. Rev bras epidemiol, v. 7, n. 3, p. 338?349, 2004. GONTIJO, B; CARVALHO. M.L.R. Leishmaniose Tegumentar Americana. Rev Soc Brasil Medic Trop., n. 36, v.1, p. 71-80, 2003. GOTO, H.; LINDOSO, J.A.L. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther, v. 8, n. 4, p. 419-43, 2010. GOULART, C.M. S?ntese e Avalia??o da Atividade Anticorrosiva de Tiossemicarbazonas, Chalconas-tiossemicarbazonas e 1-Tiocarbamoil-4,5-diidropiraz?is. 2015. Tese (Doutorado em Qu?mica) - Universidade Federal Rural do Rio de Janeiro, Rio de Janeiro, 2015. GRIMALDI Jr., G.; TESH, R.B. Leishmaniasis of the New World: current concepts and implications for future research. Clin Microb Rev., v. 6, p. 230?250, 1993. GREEN, L.C.; WAGNER, D.A.; GLOGOWSKI, J.; SKIPPER, P.L.; WISHNOK, J.S.; TANNENBAUM, S.R. Analysis of nitrate, nitrite, and [15 N] nitrate in biological fluids. Analytical Biochemistry, n. 126, p.131-138, 1982. GUERRA, J.A.; PRESTES, S.R.; SILVEIRA, H.; COELHO, L.I.; GAMA, P.; MOURA, A.; AMATO, V.; BARBOSA, M. D.; FERREIRA, L.C. Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis; v. 5, n. 3, p. 980, 2011. HAMILTON, C. J. et al. Ellman's-reagent-mediated regeneration of trypnothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. Biochem. J., v. 369, p. 529-537, 2003. JHA, T.K.; SUNDAR, S.; THAKUR, C.P.; BACHMANN, P.; KARBWANG, J.; FISCHER, C.; VOSS, A.; BERMAN, J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med, v. 341, n. 24, p. 1795-1800, 1999. JOHNSTONE, A.; THORPE, R. lmmunochemistry in Practice, Blackwell. Scientific Publications. 1982. KUMAR, N.; CHAUHAN, A; DRABU, S. Biomed. Pharmacother. v. 65, n. 5, p. 375-380, 2011. LUO, Y.; SONG, R.; LI, Y.; ZHANG, S.; LIU, Z.; FU, J.; ZHU, H. Bioorganic & Medicinal Chemistry Letters. v. 22, n. 9, p. 3039-3043, 2012 MARSDEN, P.D. Mucosal leishmaniasis (Espundia Escomel,1911). Transactions of the Royal Society of Tropical Medicine and Hygiene, v. 80, p. 859-876, 1986. MARZOCHI, M.C.A.; TEIXEIRA, P.C.; MARZOCHI, K.B.F.; CONCEI??O, N.F.; COUTINHO, W.; BRITO, D.B. Vacuum aspiratory puncture system for Leishmania culturing, isolation and transport. Preliminary report. Rev. Inst. Med. Trop. S?o Paulo, v. 35, p. 301-303, 1993. MARZOCHI, M.C.A. Doen?as infecto-parasit?rias: Leishmanioses no Brasil: as leishmanioses tegumentares. J Bras Med., v.63, p. 82-104, 1992. MARZOCHI, M.C.; MARZOCHI, K.B.F. Tegumentary and visceral leishmaniasis in Brazil: emerging anthropozoonosis and for their control. Cadernos de Sa?de P?blica n. 10, v. 2, p. 359-375, 1994. MELOS, J.L.R.; TORRES-SANTOS, E.C.; FAI?ES, V.S.; CATARINA DE NIGRIS DEL CISTIA , C.N.D.; SANT'ANNA, C.M.R.; RODRIGUES-SANTOS, C.E.; ECHEVARRIA, A. Novel 3,4-methylenedioxyde-6-X-benzaldehyde-thiosemicarbazones: Synthesis and antileishmanial effects against Leishmania amazonensis. European Journal of Medicinal Chemistry, n. 103, p. 409 e 417, 2015. MELLO, M.V.P. et al. A comprehensive review of chalcone derivatives as antileishmanial agentes. European Journal of Medicinal Chemistry, v. 150, p. 920-929, 2018. MENDON?A-FILHO, R.R.; RODRIGUES, I. A.; ALVIANO, D.S.; SANTOS, L.S.; SOARES, R.M.A.; ALVIANO, C.S.; LOPES, A.H.C.S.; ROSA, M.S.S. Leishmanicidal activity of polyphenolic-rich extract from husk fiber of Cocos nicifera Linn. (Palmae). Rev. Microbiol., v. 155, p.136-143, 2004. MONDAL, R.; GUPTA, A. D.; MALLIK, A. K. Tetrahedron Lett., v. 52, n. 39, p. 5020-5024, 2011. MONZOTE, L.; STAMBERG, W.; PATEL, A.; ROSENAU, T.; MAES, L.; COS, P.; GILLE, L. Current Treatment of Leishmaniasis: A sand flies. International Journal for Parasitology, n. 37, p. 1097, 2007. MORENO, S. N. J.; CARNIERI. E. G. S.; DOCAMPO, R. Inhibition of Trypanossoma cruzi trypanothione reductase by crystal violet. Mol Biochem Parasitol., v. 67, p. 313- 320, 1994. M?LLER, S.; LIEBAU, E.; ROLF, D.W.; KRAUTH-SIEGEL, R.L. Thiol-based redox metabolism of protozoan parasites. Trends in Parasitology, v. 19, n. 7, p. 320-328, 2003. MURRAY, H.W.; BERMAN, J.D.; DAVIES, C.R.; SARAVIA, N.G. Advances in leishmaniasis. Lancet, n. 366, p. 1561-1577, 2005 MYLER, P.J.; FASEL, N. Leishmaniasis: epidemiological Trends and Diagnosis. Leishmania - After the genome, p. 1-14, 2008. HEBY, O.; PERSSON, L.; RENTALA, M. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas? disease, and leishmaniasis. Amino Acids, v. 33, n. 2, p. 359-366, 2007. NAGLE, A.S.; KHARE, S.; KUMAR, A.B.; SUPEK, F.; BUCHYNSKYY, A.; MATHISON, C.J.N.; MOLTENI, V. Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chemical Reviews, n. 114, p. 11305, 2014. NEUBER, H. Leishmaniasis. Journal der Deutschen Dermatologischen Gesellschaft, n. 6, p. 754-764, 2008. NOGUEIRA, Y.L.; ODORIZZI, R.M.; NAKAMURA, P.M.A. Comparison of the immune parameters of dogs infected with visceral leishmaniasis using Western blot and neutralization techniques. Rev Inst Med Trop., S?o Paulo, v. 49, n. 6, p. 379-384, 2007. OLIVEIRA, L.F.; SCHUBACH, A.O.; MARTINS, M.M.; PASSOS, S.L.; OLIVEIRA, R.V.; MARZOCHI, M.C.; ANDRADE, C.A. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica, 118, p. 87-96, 2011. ORGANIZACION MUNDIAL DE LA SALUD ? Lucha contra las leishmaniasis. Ginebra, OMS, (S?rie de Informes T?cnicos, 793) 178p.1990. ORGANIZA??O MUNDIAL DE SA?DE (OMS). Temas de Salud- Leishmaniasis. 2012. Dispon?vel em: < http://www.who.int/leishmaniasis/en/> Acesso em: 24 mar de 2017. ORGANIZA??O PAN-AMERICANA DA SA?DE: Leishmanioses: Informe Epidemiol?gico das Am?ricas: Washington: Organiza??o Pan-Americana da Sa?de; 2018. Dispon?vel em www.paho.org/leishmaniasis ?ZDEMIR, A.; ALTINTOP, M.D.; TURAN-ZITOUNI, G.; ?IFT?I, G.A.; ERTORUN, I.; ALATAS, ?.; KAPLANCICLI, Z.A. Synthesis and Evaluation of New Indole-Based Chalcones as Potential Antiinflammatory Agents, European Journal of Medicinal Chemistry, n. 89, p. 304, 2015. PALATNICK DE SOUSA, C.B. et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg, v. 65, n. 5, p. 510-517, 2001. PENNA, H. A. Leishmaniose visceral no Brasil. Brasil-M?dico, v. 48, p. 949-950, 1934. PESSOA, S.B. Parasitologia M?dica. 11. ed., Rio de Janeiro: Guanabara Koogan; 1982. PIMENTEL, M.I.F.; BAPTISTA, C.; RUBIN, E.F.; VASCONCELLOS, E.F.; LYRA, M.R.; SALGUEIRO, M.M. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report. Rev Soc Bras Med Trop., n. 44, p. 254, 2011. PISCOPO, T.V.; MALLIA, A.C. Leishmaniasis. Postgrad Med J, v. 82, n. 972, p.649-657, 2006. POCAI, E.A. et al. Leishmaniose visceral (calazar). Cinco casos em Santa Maria, Rio Grande do Sul, Brasil. Ci?nc Rural, v. 28, n. 3, p. 501-505, 1998. RANI, M.; YUSUF, M; KHAN, S. J. Saudi Chem. Soc., n. 16, p. 431, 2012. REY, L. Bases da Parasitologia M?dica, 2? ed. Ed. Guanabara Koogan, Rio de Janeiro, p. 349, 2001. RIGOL, C.; OLEA-AZAR, C.; MENDIZ?BAL, F.; OTERO, L.; AMBINO, D.; GONZ?LEZ, M.; CERECETTO, H. Electrochemical and ESR study of 5-nitrofuryl-containing thiosemicarbazones antiprotozoal drugs. Spectrochimica Acta, Part A., v. 61, n. 13-14, p. 2933-2938, 2005. SANTOS, D.O.; COUTINHO, C.E.R.; MADEIRA, M.F.; BOTTINO, C.G.; VIEIRA, R.T.; NASCIMENTO, S.B.; BERNARDINO, A.; BOURGUIGNON, S.C.; CORTE-REAL, S.; Pinho, R.T.; RODRIGUES, C.R.; CASTRO, H.C. Leishmaniasis treatment-a challenge that remains: a review. Parasitol. Res., v. 103, p. 1?10, 2008. SANTOS, M. et al. Riboflavin biosynthesis in Saccharomyces cerevisiae. Cloning, characterization, and expression of the RIB5 gene encoding riboflavin synthase. J Biol Chem, v. 270, n. 1, p. 437-44, 1995. SANTOS, S.O. et al. Incrimination of Lutzomyia cruzi as a vector of American Visceral Leishmaniasis. Medical and Veterinary Entomology, n. 2, p. 315-317, 1998. SCARIM, C.B. et al. Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. European Journal of Medicinal Chemistry, n. 162, p. 378-395, 2019. SHAW, J. J. Further thoughts on the use of the name Leishmania (Leishmania) infantum chagasi for the aetiological agent of American visceral leishmaniasis. Mem?rias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 101, n. 5, p. 577-579, 2006. SILVA, A.C. et al. Aryl thiosemicarbazones: in vitro and immunomodulatory activities against L. amazonensis. Exp. Parasitol., n. 177, p. 57-65, 2017. SILVA, F.S. Patologia e patog?nese da leishmaniose visceral canina. Revista Tr?pica ? Ci?ncias Agr?rias e Biol?gicas, v. 1, n. 1, p. 20-31, 2007. SINGH, S.; SIVAKUMAR, R. Challenges and new discoveries in the treatment of leishmaniasis. J Inf Chemother, v. 10, n. 6, p. 307-315, 2004. SisLeish-OPAS/OMS: Dados reportados pelos Programas Nacionais de Leishmanioses/Servi?os de Vigil?ncia. Acesso em: 01 de Dezembro de 2017. SOARES, R.O.A.; ECHEVARRIA, A.; BELLIENY, M.S.S.; PINHO, R.T.; DE LEO, R.M.M.; SEGUINS, W.S.; MACHADO, G.M.; CANTO-CAVALHEIRO, M.M.; LEON, L.L. Evaluation of thiosemicarbazones and semicarbazones as potential agents anti-Trypanosoma cruzi. Experimental Parasitology, n. 129, p. 381?387, 2011. STRAZZULLA, A.; COCUZZA, S.; PINZONE, M. R.; POSTORINO, M.C.; COSENTINO, S.; SERRA, A.; CACOPARDO, B.; NUNNARI, G. Mucosal Leishmaniasis: An Underestimated Presentation of a Neglected Disease. Biomed Research International, 2013. STUART, K.; BRUN,R.; CROFT, S.; FAIRLAMB, A.; GURTLER, R.E.; McKERROW, J., REED, S.; TARLETON, R. Kinetoplastids: related protozoan pathogens, different diseases. Journal of Clinical Investigation; v. 118, n. 4, p. 1301-1310, 2008. SUNDAR, S.; CHAKRAVARTY, J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs, v. 17, n. 5, p. 787-794, 2008. TAJUDDEEN, N.; ISAH M.B.; SULEIMAN M.A.; van HEERDEN F.R.; IBRAHIM M.A. The chemotherapeutic potential of chalcones against leishmaniases: a review. Int J Antimicrob Agents., n. 51, v. 3, p. 311-318, 2018. TEMPONE, A.G.; BORBOREMA, S.E.T.; ANDRADE Jr, H.F.; GUALDA, N.C.A.; YOGI, A.; CRAVALHO, C.S.; BACHIEGA, D.; LUPO, F.N.; BONOTTO, S.V.; FISCHER, D.C.H. Antiprotozoal activity of Brazilian plant extracts from isoquinoline alkaloidsproducing families. Phytomedicine, v.12, p. 382-390, 2005. Tuon, F.F.; Amato, V.S.; Graf, M.E.; Siqueira, A.M.; Nicodemo, A.C.; Neto, V.A. Treatment of New World cutaneous leishmaniasis ? a systematic review with a meta-analysis. Int J Dermatol, v. 4, n. 2, p. 109-124, 2008. van GRIENSVEN, J.; DIRO, E. Visceral Leishmaniasis. Infectious Disease Clinics of North America, v. 26, p. 309, 2012. ORGANIZA??O MUNDIAL DE SA?DE (OMS). Temas de Salud- Leishmaniasis. 2012. Dispon?vel em: < http://www.who.int/leishmaniasis/en/> Acesso em: 24 mar de 2017. World Health Organization (WHO) 2013. http://apps.who.int/tdr/publications/tdr-image-library?idNumber=00061046. Acessado em 30 de julho de 2017. World Health Organization 2010 (OMS/WHO). http://apps.who.int/tdr/publications/tdr-image-library?idNumber=00061043. Acessado em 5 de Agosto de 2017. World Health Organization (WHO), 2015. 1-164p. WHO 2010a. Technical Report Series. Control of the leishmaniases. Dispon?vel em: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. Acesso em 10 de fevereiro de 2017. WHO 2010b. World Health Organization. First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases. Dispon?vel em: http://www.who.int/neglected_diseases/2010report/en/. Acesso em 20 de novembro de 2017. WHO 2012. Second WHO Report on Neglected Tropical Diseases.Treatment recommendation for leishmaniasis. Dispon?vel em: http:// www.who.int/leishmaniases/research/978924129496_pp67_71.pdf?ua=1. Acesso em 20 de abril de 2017. WHO - World Health Organization, 2019. Dispon?vel em: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis (14 de mar?o de 2019). WYLLIE, S.; CUNNINGHAM, M.L.; FAIRLAMB, A.H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem, v. 279, n. 38, p. 39925-39932, 2004. ZAVERUCHA, T.V. Vacina??o murina com fra??es subcelulares de Leishmania amazonensis sob modula??o de Mycobacterium bovis BCG e ciclofosfamida. 2005. Tese (Doutorado em Biologia Parasit?ria) Instituto Oswaldo Cruz, Funda??o Oswaldo Cruz, Rio de Janeiro, 2005.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal Rural do Rio de Janeiro
dc.publisher.program.fl_str_mv Programa de P?s-Gradua??o em Ci?ncia, Tecnologia e Inova??o em Agropecu?ria
dc.publisher.initials.fl_str_mv UFRRJ
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv Pr?-Reitoria de Pesquisa e P?s-Gradua??o
publisher.none.fl_str_mv Universidade Federal Rural do Rio de Janeiro
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da UFRRJ
instname:Universidade Federal Rural do Rio de Janeiro (UFRRJ)
instacron:UFRRJ
instname_str Universidade Federal Rural do Rio de Janeiro (UFRRJ)
instacron_str UFRRJ
institution UFRRJ
reponame_str Biblioteca Digital de Teses e Dissertações da UFRRJ
collection Biblioteca Digital de Teses e Dissertações da UFRRJ
bitstream.url.fl_str_mv http://localhost:8080/tede/bitstream/jspui/5651/4/2019+-+Edin%C3%A9a+Pastro+Mendes.pdf.jpg
http://localhost:8080/tede/bitstream/jspui/5651/3/2019+-+Edin%C3%A9a+Pastro+Mendes.pdf.txt
http://localhost:8080/tede/bitstream/jspui/5651/2/2019+-+Edin%C3%A9a+Pastro+Mendes.pdf
http://localhost:8080/tede/bitstream/jspui/5651/1/license.txt
bitstream.checksum.fl_str_mv cc73c4c239a4c332d642ba1e7c7a9fb2
9b114330abf45affc0434ecac00917c5
87d33da433ee3426cb9cb1ee14afab29
7b5ba3d2445355f386edab96125d42b7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações da UFRRJ - Universidade Federal Rural do Rio de Janeiro (UFRRJ)
repository.mail.fl_str_mv bibliot@ufrrj.br||bibliot@ufrrj.br
_version_ 1797220366624489472